XNASALMS
Market cap420mUSD
Jan 15, Last price
7.73USD
1D
1.18%
1Q
-30.49%
IPO
-38.36%
Name
Alumis Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-155m
L+38.47%
CFO
-130m
L+20.66%
Profile
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2023‑12 | 2022‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | 159,458 | 113,850 |
Unusual Expense (Income) | ||
NOPBT | (159,458) | (113,850) |
NOPBT Margin | ||
Operating Taxes | ||
Tax Rate | ||
NOPAT | (159,458) | (113,850) |
Net income | (154,993) 38.47% | (111,930) |
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | 90,167 | 101,627 |
BB yield | ||
| Debt | ||
Debt current | 1,720 | 1,310 |
Long-term debt | 63,440 | 938 |
Deferred revenue | ||
Other long-term liabilities | 1,771 | 4,116 |
Net debt | 15,184 | (91,961) |
| Cash flow | ||
Cash from operating activities | (129,975) | (107,722) |
CAPEX | (4,499) | (2,406) |
Cash from investing activities | 60,472 | (68,751) |
Cash from financing activities | 89,682 | 101,627 |
FCF | (190,207) | |
| Balance | ||
Cash | 48,952 | 93,071 |
Long term investments | 1,024 | 1,138 |
Excess cash | 49,976 | 94,209 |
Stockholders' equity | 11,055 | 76,022 |
Invested Capital | 59,406 | 20,104 |
ROIC | ||
ROCE | ||
| EV | ||
Common stock shares outstanding | 51,845 | 7,498 |
Price | ||
Market cap | ||
EV | ||
EBITDA | (158,174) | (113,600) |
EV/EBITDA | ||
Interest | ||
Interest/NOPBT | ||